| Name | Title | Contact Details |
|---|
AdPharma is a Arlington Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Connect Biopharma (Nasdaq: CNTB) is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research. With operations and expertise in China, the United States and Australia and clinical development activities in those geographies as well as Europe, Connect Biopharma is building a rich pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent drug candidates against immune targets. Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets.
Threshold Pharmaceuticals, Inc. is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Eli Lilly and Company is a global pharmaceutical corporation based in Indianapolis, Indiana, with a history of nearly 150 years. Founded in 1876 by Colonel Eli Lilly, the company has grown to become one of the largest pharmaceutical enterprises in the world, employing over 42,900 people as of 2023. Lilly focuses on biomedical research, drug discovery, and manufacturing, with a diverse portfolio that includes treatments for diabetes, oncology, neuroscience, and immunology. Lilly pioneered the first commercially available insulin product in 1923 and continues to innovate with modern offerings like Trulicity and Mounjaro for diabetes management. The company also develops drugs such as Verzenio for breast cancer and Zyprexa for psychiatric disorders. With a strong emphasis on research and development, Lilly is recognized for its commitment to improving drug accessibility and patient care through partnerships with healthcare providers and systems worldwide.
Engineering next‑generation, brain‑penetrant cancer therapies.